Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05762952
PHASE1

Effect of Dapagliflozin on Microvascular Function in Women With Symptoms of Coronary Artery Disease

Sponsor: University of Virginia

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to test the effects of a drug (in the drug class called sodium-glucose cotransporter 2 inhibitors) in women who have symptoms of ischemic heart disease. The main questions the study aims to answer are: Does blood flow in the heart improve with study drug? Participants will be randomly assigned to a 12-week course of the study drug, dapagliflozin 10mg, or placebo. Blood flow in the heart will be assessed using stress cardiac magnetic resonance imaging at baseline and 12 weeks. The researchers will compare the results from the two groups.

Official title: A Single-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate Microvascular Disease After 12 Weeks of Therapy With Sodium-glucose Co-transporter 2 Inhibitor Compared to Placebo in Symptomatic Women With Non-obstructive Coronary Artery Disease

Key Details

Gender

FEMALE

Age Range

18 Years - 99 Years

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2023-06-06

Completion Date

2026-03-31

Last Updated

2025-08-22

Healthy Volunteers

No

Interventions

DRUG

Dapagliflozin 10mg Tab

Once daily oral dapagliflozin 10mg

DRUG

Placebo

Placebo capsules formulated by pharmacy to be indistinguishable from active drug

Locations (1)

University of Virginia

Charlottesville, Virginia, United States